无心力衰竭患者心肌梗死后使用β受体阻滞剂
该开放标签、终点盲法评估的随机对照试验在丹麦和挪威纳入心肌梗死后14天内、左室射血分数≥40%的患者,1:1随机分配至长期β受体阻滞剂治疗组或不使用β受体阻滞剂组。共5574例患者纳入主要分析(β受体阻滞剂组2783例,无β受体阻滞剂组2791例),中位随访3.5年。主要终点(全因死亡或主要不良心血管事件复合终点)在β受体阻滞剂组发生率为14.2%,无β受体阻滞剂组为16.3%(HR 0.85,95%CI 0.75-0.98,P=0.03)。结论认为,在左室射血分数≥40%的心肌梗死患者中,β受体阻滞剂治疗较无β受体阻滞剂治疗降低死亡或主要不良心血管事件风险。
要点
- 心肌梗死且左室射血分数≥40%的患者,长期β受体阻滞剂治疗使主要终点事件(全因死亡或主要不良心血管事件)风险降低(14.2% vs 16.3%,HR 0.85,95%CI 0.75-0.98,P=0.03)。
- β受体阻滞剂组心肌梗死发生率为5.0%,无β受体阻滞剂组为6.7%(HR 0.73,95%CI 0.59-0.92)。
- 全因死亡在β受体阻滞剂组为4.2%,无β受体阻滞剂组为4.4%;两组安全性结局未见明显差异。
- 该试验在丹麦和挪威进行,纳入心肌梗死后14天内、左室射血分数≥40%的患者,中位随访3.5年。
适用人群与场景
- 心肌梗死患者,左室射血分数至少40%,在事件后14天内入组。
- 研究在丹麦和挪威进行。
诊断标准与关键阈值
- 左室射血分数至少40%。
- 心肌梗死后14天内开始长期β受体阻滞剂治疗或无β受体阻滞剂治疗。
处置流程与药物剂量
- 长期β受体阻滞剂治疗需在心肌梗死后14天内开始,具体药物、剂量、途径和频次原文未写明。
研究设计与关键结果
- 开放标签、终点盲法评估的随机对照试验,在丹麦和挪威进行,共5574例患者随机分组并纳入主要分析:β受体阻滞剂组2783例,无β受体阻滞剂组2791例。
- 中位随访3.5年(四分位距2.2至4.6年),主要终点(全因死亡或主要不良心血管事件复合终点)在β受体阻滞剂组发生394例(14.2%),无β受体阻滞剂组发生454例(16.3%)(HR 0.85,95%CI 0.75-0.98,P=0.03)。
- 全因死亡在β受体阻滞剂组为4.2%,无β受体阻滞剂组为4.4%。
- 心肌梗死发生率在β受体阻滞剂组为5.0%,无β受体阻滞剂组为6.7%(HR 0.73,95%CI 0.59-0.92)。
- 非计划冠状动脉血运重建率在β受体阻滞剂组为3.9%,无β受体阻滞剂组为3.9%。
- 缺血性卒中在β受体阻滞剂组为1.6%,无β受体阻滞剂组为1.3%;心力衰竭在β受体阻滞剂组为1.5%,无β受体阻滞剂组为1.9%;恶性室性心律失常在β受体阻滞剂组为0.5%,无β受体阻滞剂组为0.6%。
- 两组安全性结局未见明显差异。
证据类型、等级与局限
- 证据类型:开放标签、终点盲法评估的随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于心肌梗死且左室射血分数至少40%的患者,作者结论认为β受体阻滞剂治疗较无β受体阻滞剂治疗降低死亡或主要不良心血管事件风险。
指南或共识出处
- BETAMI-DANBLOCK,ClinicalTrials.gov注册号NCT03646357和NCT03778554;由挪威Health South-East研究项目等资助。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The evidence supporting beta-blocker therapy after myocardial infarction was established before the introduction of modern coronary reperfusion therapy and secondary prevention strategies.
METHODS: In an open-label, randomized trial with blinded end-point evaluation, conducted in Denmark and Norway, we assigned patients who had had a myocardial infarction and who had a left ventricular ejection fraction of at least 40%, in a 1:1 ratio, to receive long-term beta-blocker therapy within 14 days after the event or no beta-blocker therapy. The primary end point was a composite of death from any cause or major adverse cardiovascular events (new myocardial infarction, unplanned coronary revascularization, ischemic stroke, heart failure, or malignant ventricular arrhythmias).
RESULTS: A total of 5574 patients underwent randomization and were included in the main analyses - 2783 in the beta-blocker group and 2791 in the no-beta-blocker group. After a median follow-up of 3.5 years (interquartile range, 2.2 to 4.6), a primary end-point event had occurred in 394 patients (14.2%) in the beta-blocker group and in 454 patients (16.3%) in the no-beta-blocker group (hazard ratio, 0.85; 95% confidence interval [CI], 0.75 to 0.98; P = 0.03). Death from any cause occurred in 4.2% of the patients in the beta-blocker group and in 4.4% of those in the no-beta-blocker group; myocardial infarction occurred in 5.0% and 6.7%, respectively (hazard ratio, 0.73; 95% CI, 0.59 to 0.92), unplanned coronary revascularization in 3.9% and 3.9%, ischemic stroke in 1.6% and 1.3%, heart failure in 1.5% and 1.9%, and malignant ventricular arrhythmias in 0.5% and 0.6%. No apparent differences in safety outcomes were observed between the groups.
CONCLUSIONS: Among patients with a myocardial infarction and a left ventricular ejection fraction of at least 40%, beta-blocker therapy led to a lower risk of death or major adverse cardiovascular events than no beta-blocker therapy. (Funded by the Health South-East research program in Norway and others; BETAMI-DANBLOCK ClinicalTrials.gov numbers, NCT03646357 and NCT03778554.).
参考来源
- Munkhaugen J, Kristensen AMD, Halvorsen S, et al. Beta-Blockers after Myocardial Infarction in Patients without Heart Failure. N Engl J Med. 2025. PMID: 40888716. doi:10.1056/NEJMoa2505985
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。